2-Methoxyestradiol and paclitaxel have similar effects on the cell cycle and induction of apoptosis in prostate cancer cells

Cancer Letters

Volumn 231, Issue 1, 2006, Pages 49-64

  Perez Stable, Carlos ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Cyclin A; Cyclin B1; Mitotic block; Prostate cancer

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 METHOXYESTRADIOL; CYCLIN A; CYCLIN B1; CYCLIN DEPENDENT KINASE INHIBITOR; PACLITAXEL; PROTEIN P53; X LINKED INHIBITOR OF APOPTOSIS;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL ACTIVATION; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL LINE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; LOW DRUG DOSE; MITOSIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; WILD TYPE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL CYCLE; CYCLIN-DEPENDENT KINASES; ESTRADIOL; HUMANS; MALE; PACLITAXEL; PROSTATIC NEOPLASMS; TUBULIN MODULATORS; TUMOR CELLS, CULTURED;

EID: 28844433297     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.01.018     Document Type: Article

References (45)

1. B.T. Zhu, and A.H. Conney Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis? Cancer Res. 58 1998 2269 2277
2. V.S. Pribluda, E.R. Gubish, T.M. LaValle, A. Treston, G.M. Swartz, and S.J. Green 2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate Cancer Met. Rev. 19 2000 173 179
3. N.J. Lakhani, M.A. Sarkar, J. Venitz, and W.D. Figg 2-Methoxyestradiol, a promising anticancer agent Pharmacotherapy 23 2003 165 172
4. S.L. Mooberry Mechanism of action of 2-methoxyestradiol: new developments Drug Resist. Update 6 2003 355 361
5. L.R. Qadan, C.M. Perez-Stable, C. Anderson, G. D'Ippolito, A. Herron, G.A. Howard, and B.A. Roos 2-Methoxyestradiol induces G2/M arrest and apoptosis in prostate cancer Biochem. Biophys. Res. Commun. 285 2001 1259 1266
6. A.P. Kumar, G.E. Garcia, and T.H. Slaga 2-methoxyestradiol blocks cell-cycle progression at G(2)/M phase and inhibits growth of human prostate cancer cells Mol. Carcinog. 31 2001 111 124
7. T.M. LaValle, X.H. Zhan, C.J. Herbstritt, E.C. Kough, S.J. Green, and V.S. Pribluda 2-Methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptors alpha and beta Cancer Res. 62 2002 3691 3697
8. S. Bu, A. Blaukat, X. Fu, N.E. Heldin, and M. Landstrom Mechanisms for 2-methoxyestradiol-induced apoptosis of prostate cancer cells FEBS Lett. 531 2002 141 151
9. A. Basu, and S. Haldar Identification of a novel Bcl-xL phosphorylation site regulating the sensitivity of taxol- or 2-methoxyestradiol-induced apoptosis FEBS Lett. 538 2003 41 47
10. K. Shimada, M. Nakamura, E. Ishida, M. Kishim, and N. Konishi Roles of p38- and c-jun NH2-terminal kinase-mediated pathways in 2-methoxyestradiol- induced p53 induction and apoptosis Carcinogenesis 24 2003 1067 1075
11. T.M. LaVallee, X.H. Zhan, M.S. Johnson, C.J. Herbstritt, G. Swartz, and M.S. Williams 2-Methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway Cancer Res. 63 2003 468 475
12. N.J. Mabjeesh, D. Escuin, T.M. LaVallee, V.S. Pribluda, G.M. Swartz, and M.S. Johnson 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF Cancer Cell 3 2003 363 375
13. T.H. Wang, H.S. Wang, and Y.K. Soong Paclitaxel-induced cell death: where the cell cycle and apoptosis come together Cancer 88 2000 2619 2628
14. S.C. Shen, T.S. Huang, S.H. Jee, and M.L. Kuo Taxol-induced p34cdc2 kinase activation and apoptosis inhibited by 12-O-tetradecanoylphorbol-13- acetate in human breast MCF-7 carcinoma cells Cell Growth Diff. 9 1998 23 29
15. Y.H. Ling, U. Consol, C. Tornos, M. Andreeff, and R. Perez-Soler Accumulation of cyclin B1, activation of cyclin B1-dependent kinase and induction of programmed cell death in human epidermoid carcinoma KB cells treated with taxol Int. J. Cancer 75 1998 925 932
16. R. Panvichian, K. Orth, M.J. Pilat, M.L. Day, K.C. Day, and C. Yee Signaling network of paclitaxel-induced apoptosis in the LNCaP prostate cancer cell line Urology 54 1999 746 752
17. D.S. O'Connor, N.R. Wall, A.C. Porter, and D.C. Altieri A p34(cdc2) survival checkpoint in cancer Cancer Cell 2 2002 43 54
18. D.S. O'Connor, D. Grossman, J. Plescia, F. Li, H. Zhang, and A. Villa Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin Proc. Natl Acad. Sci. USA 97 2000 13103 13107
19. J.S. Horoszewicz, S.S. Leong, E. Kawinski, J.P. Kerr, H. Rosenthal, and T.M. Chu LNCaP model of human prostatic carcinoma Cancer Res. 43 1983 1809 1818
20. K.R. Stone, D.D. Mickey, H. Wunderli, G.H. Mickey, and F. Paulson Isolation of a human prostate carcinoma cell line (DU 145) Int. J. Cancer 21 1978 274 281
21. M.E. Kaighn, K.S. Narayan, Y. Ohnuki, J.F. Lechner, and L.W. Jones Establishment and characterization of a human prostatic carcinoma cell line (PC-3) Invest. Urol. 17 1979 16 23
22. A. Krishan Rapid DNA content analysis by the propidium iodide-hypotonic citrate method Methods Cell Biol. 33 1990 121 125
23. N.S. Gray, L. Wodicka, A.M. Thunnissen, T.C. Norman, S. Kwon, and F.H. Espinoza Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors Science 281 1998 533 538
24. C. Schultz, A. Link, M. Leost, D.W. Zaharevitz, R. Gussio, and E.A. Sausville Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity J. Med. Chem. 42 1999 2909 2919
25. F.H. Sarkar, W. Sakr, Y.W. Li, J. Macoska, D.E. Ball, and J.D. Crissman Analysis of retinoblastoma (RB) gene deletion in human prostatic carcinomas Prostate 21 1992 145 152
26. A.G. Carroll, H.J. Voeller, L. Sugars, and E.P. Gelmann p53 oncogene mutations in three human prostate cancer cell lines Prostate 23 1993 123 134
27. C.H. Yam, T.K. Fung, and R.Y. Poon Cyclin A in cell cycle control and cancer Cell Mol. Life Sci. 59 2002 1317 1326
28. K.L. King, and J.A. Cidlowski Cell cycle regulation and apoptosis Annu. Rev. Physiol. 60 1998 601 617
29. W.S. El-Deiry, T. Tokino, V.E. Velculescu, D.B. Levy, R. Parsons, and J.M. Trent WAF1, a potential mediator of p53 tumor suppression Cell 75 1993 817 825
30. P. Liston, W.G. Fong, and R.G. Korneluk The inhibitors of apoptosis: there is more to life than Bcl2 Oncogene 22 2003 8568 8580
31. P. Clute, and J. Pines Temporal and spatial control of cyclin B1 destruction in metaphase Nat. Cell Biol. 1 1999 82 87
32. M. Castedo, J.L. Perfettini, T. Roumier, and G. Kroemer Cyclin-dependent kinase-1: linking apoptosis to cell cycle and mitotic catastrophe Cell Death. Differ. 9 2002 1287 1293
33. J. Bartek, and J. Lukas Pathways governing G1/S transition and their response to DNA damage FEBS Lett. 490 2001 117 122
34. P. Giannakakou, R. Robey, T. Fojo, and M.V. Blagosklonny Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity Oncogene 20 2001 3806 3813
35. Y.N. Chen, S.K. Sharma, T.M. Ramsey, L. Jiang, M.S. Martin, and K. Baker Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists Proc. Natl Acad. Sci. 96 1999 4325 4329
36. O. Tetsu, and F. McCormick Proliferation of cancer cells despite CDK2 inhibition Cancer Cell 3 2003 233 245
37. T. Mukhopadhyay, and J.A. Roth Superinduction of wild-type p53 protein after 2-methoxyestradiol treatment of Ad5p53-transduced cells induces tumor cell apoptosis Oncogene 17 1998 241 246
38. A.D. Schimmer, K. Welsh, C. Pinilla, Z. Wang, M. Krajewska, and M.J. Bonneau Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity Cancer Cell 5 2004 25 35
39. C.P. Ng, A. Zisman, and B. Bonavida Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance Prostate 53 2002 286 299
40. J.P. Carson, M. Behnam, J.N. Sutton, C. Du, X. Wang, and D.F. Hunt Smac is required for cytochrome c-induced apoptosis in prostate cancer LNCaP cells Cancer Res. 62 2002 18 23
41. I. Lebedeva, R. Rando, J. Ojwang, P. Cossum, and C.A. Stein Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity Cancer Res. 60 2000 6052 6060
42. X. Li, M. Marani, R. Mannucci, B. Kinsey, F. Andriani, and I. Nicoletti Overexpression of BCL-X(L) underlies the molecular basis for resistance to staurosporine-induced apoptosis in PC-3 cells Cancer Res. 61 2001 1699 1706
43. C.M. Perez-Stable, G.G. Schwartz, A. Farinas, M. Finegold, L. Binderup, G.A. Howard, and B.A. Roos The Gγ/T-15 transgenic mouse model of androgen-independent prostate cancer: target cells of carcinogenesis and the effect of the vitamin D analogue EB 1089 Cancer Epidemiol Biomarkers Prev. 11 2002 555 563
44. H. Kao, J.A. Marto, T.K. Hoffmann, J. Shabanowitz, S.D. Finkelstein, and T.L. Whiteside Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells J. Exp. Med. 194 2001 1313 1323
45. D.P. Petrylak Chemotherapy for androgen-independent prostate cancer Semin. Urol. Oncol. 20 2002 31 35